Pharmacogenetics of tacrolimus: Ready for clinical translation

Kidney International Supplements

Volumn 1, Issue 2, 2011, Pages 58-62

  Coto, Eliecer ^a,b,c,d   Tavira, Beatriz ^a   Suárez Álvarez, Beatriz ^d,e   López Larrea, Carlos ^c,d,e   Díaz Corte, Carmen ^b,d,e   Ortega, Francisco ^b,c,d,e   Álvarez, Victoria ^a  

^a Hospital Universitario   (Spain)

^b UNIVERSITY OF OVIEDO   (Spain)

^c Section of Nephrology   (Spain)

^d Red de Investigación Renal   (Spain)

^e HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

Author keywords

cytochromes P450; pharmacogenetics; pharmacokinetics; renal transplantation; tacrolimus

Indexed keywords

EID: 84884211153     PISSN: 21571724     EISSN: 21571716     Source Type: Journal    
DOI: 10.1038/kisup.2011.14     Document Type: Article

References (52)

1. Cell Liu 66 807 1991 10.1016/0092-8674(91)90124-H Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK 506 complexes
2. Physiol Rev Rusnak 80 1483 2000 10.1152/physrev.2000.80.4.1483 Calcineurin: form and function
3. Drugs Spencer 54 925 1997 10.2165/00003495-199754060-00009 Tacrolimus. An update of its pharmacology and clinical efficacy in the management of organ transplantation
4. Clin J Am Soc Nephrol Naesens 4 481 2009 10.2215/CJN.04800908 Calcineurin inhibitor nephrotoxicity
5. Am J Nephrol Friedman 5 196 1985 10.1159/000166932 Posttransplant diabetes in kidney transplant recipients
6. Kidney Int Cosio 59 732 2001 10.1046/j.1523-1755.2001.059002732.x Post-transplant diabetes mellitus: increasing incidence in renal allograft recipients transplanted in recent years
7. Transplantation Kershner 62 920 1996 10.1097/00007890-199610150-00009 Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation
8. Clin Pharmacokinet Venkataramanan 29 404 1995 10.2165/00003088-199529060-00003 Clinical pharmacokinetics of tacrolimus
9. Kidney Int Scholten 67 2440 2005 10.1111/j.1523-1755.2005.00352.x AUC-guided dosing of tacrolimus prevents progressive systemic overexposure in renal transplant recipients
10. Clin J Am Soc Nephrol Schiff 2 374 2007 10.2215/CJN.03791106 Therapeutic monitoring of calcineurin inhibitors for the nephrologist
11. Clin Chem Kamdem 51 1374 2005 10.1373/clinchem.2005.050047 Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus
12. Transplant Proc Iwasaki 23 2757 1991 Pharmacokinetic study of FK 506 in the rat
13. Arch Biochem Biophys Vincent 294 454 1992 10.1016/0003-9861(92)90711-5 In vitro metabolism of FK-506 in rat, rabbit, and human liver microsomes: identification of a major metabolite and of cytochrome P450 3A as the major enzymes responsible for its metabolism
14. Res Commun Chem Pathol Pharmacol Iwasaki 82 209 1993 Effects of twenty-three drugs on the metabolism of FK506 by human liver microsomes
15. Transplantation Thervet 76 1233 2003 10.1097/01.TP.0000090753.99170.89 Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients
16. Transplantation Tsuchiya 78 1182 2004 10.1097/01.TP.0000137789.58694.B4 Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients
17. Transplant Proc Tada 37 1730 2005 10.1016/j.transproceed.2005.02.073 Impact of CYP3A5 and MDR1(ABCB1) C3435T polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients
18. Clin Transplant Zhang 19 638 2005 10.1111/j.1399-0012.2005.00370.x Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation
19. Am J Transplant Haufroid 6 2706 2006 10.1111/j.1600-6143.2006.01518.x CYP3A5 and ABCB1 polymorphisms and tacrolimus pharmacokinetics in renal transplant candidates: guidelines from an experimental study
20. Pharmacogenet Genomics Roy 16 659 2006 10.1097/01.fpc.0000220571.20961.dd Cyp3A4, Cyp3A5, and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients
21. Clin Chem Lab Med Mourad 44 1192 2006 10.1515/CCLM.2006.229 The influence of genetic polymorphisms of cytochrome P450 3A5 and ABCB1 on starting dose-and weight-standardized tacrolimus trough concentrations after kidney transplantation in relation to renal function
22. Clin Pharmacol Ther Kuypers 82 711 2007 10.1038/sj.clpt.6100216 CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients
23. Clin Chem Lab Med Tavira 49 825 2011 10.1515/CCLM.2011.143 Pharmacogenetics of tacrolimus after renal transplantation: Analysis of polymorphisms in genes encoding 16 drug metabolizing enzymes
24. Nat Genet Kuehl 27 383 2001 10.1038/86882 Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression
25. Pharmacogenetics Hustert 11 773 2001 10.1097/00008571-200112000-00005 The genetic determinants of the CYP3A5 polymorphism
26. Ther Drug Monit Wallemacq 31 198 2009 10.1097/FTD.0b013e31819c6a37 Multi-site analytical evaluation of the Abbott ARCHITECT tacrolimus assay
27. Pharmacogenomics Xie 5 243 2004 10.1517/phgs.5.3.243.29833 Genetic variability in CYP3A5 and its possible consequences
28. Clin Pharmacol Ther Mancinelli 69 24 2001 10.1067/mcp.2001.113183 The pharmacokinetics and metabolic disposition of tacrolimus: a comparison across ethnic groups
29. Nat Rev Drug Discov Guengerich 1 359 2002 10.1038/nrd792 Cytochrome P450 enzymes in the generation of commercial products
30. Biochem Biophys Res Commun Westlind 259 201 1999 10.1006/bbrc.1999.0752 Interindividual differences in hepatic expression of CYP3A4: relationship to genetic polymorphism in the 5′-upstream regulatory region
31. Environ Mol Mutagen Amirimani 42 299 2003 10.1002/em.10199 Increased transcriptional activity of the CYP3A4*1B promoter variant
32. Expert Opin Pharmacother Ng 8 2045 2007 10.1517/14656566.8.13.2045 Pharmacogenetics as a tool for optimising drug therapy in solid-organ transplantation
33. Clin Pharmacokinet Zhang 40 159 2001 10.2165/00003088-200140030-00002 The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein
34. Clin Pharmacol Ther Marzolini 75 13 2004 10.1016/j.clpt.2003.09.012 Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance
35. Proc Natl Acad Sci USA Hoffmeyer 97 3473 2000 10.1073/pnas.97.7.3473 Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo
36. Science Kimchi-Sarfaty 315 525 2007 10.1126/science.1135308 A ‘silent’ polymorphism in the MDR1 gene changes substrate specificity
37. Pharmacogenet Genomics Wang 15 693 2005 10.1097/01.fpc.0000178311.02878.83 Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability
38. Clin Pharmacol Ther Masuda 79 90 2006 10.1016/j.clpt.2005.09.013 Intestinal MDR1/ABCB1 level at surgery as a risk factor of acute cellular rejection in living-donor liver transplant patients
39. J Am Soc Nephrol Naesens 20 2468 2009 10.1681/ASN.2009020192 Donor age and renal P-glycoprotein expression associate with chronic histological damage in renal allografts
40. Transplantation Jacobson 15 300 2011 10.1097/TP.0b013e318200e991 Novel polymorphisms associated with tacrolimus trough concentrations: results from a Multicenter Kidney Transplant Consortium
41. Bull Exp Biol Med Shchepotina 141 701 2006 10.1007/s10517-006-0257-2 Some mutations of exon-7 in cytochrome P450 gene 3A4 and their effect on 6-beta-hydroxylation of cortisol
42. Clin Pharmacol Ther Sata 67 48 2000 10.1067/mcp.2000.104391 CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity
43. Pharmacogenomics Becquemont 12 113 2010 10.2217/pgs.10.147 Practical recommendations for pharmacogenomics-based prescription: 2010 ESF-UB Conference on Pharmacogenetics and Pharmacogenomics
44. Clin Pharmacol Ther Thervet 87 721 2010 Optimization of initial tacrolimus dose using pharmacogenetic testing
45. Clin Pharmacol Ther van Gelder 87 640 2010 10.1038/clpt.2010.42 Dosing tacrolimus based on CYP3A5 genotype: will it improve clinical outcome?
46. Basic Clin Pharmacol Toxicol Quteineh 103 546 2008 10.1111/j.1742-7843.2008.00327.x Influence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients
47. Am J Transplant MacPhee 4 914 2004 10.1111/j.1600-6143.2004.00435.x The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation
48. Transplantation Min 90 1394 2010 10.1097/TP.0b013e3181fa93a4 CYP3A5 *1 allele: impacts on early acute rejection and graft function in tacrolimus-based renal transplant recipients
49. Eur J Clin Pharmacol Satoh 65 473 2009 10.1007/s00228-008-0606-3 CYP3A5 *1 allele associated with tacrolimus trough concentrations but not subclinical acute rejection or chronic allograft nephropathy in Japanese renal transplant recipients
50. Pharmacogenet Genomics Hesselink 18 339 2008 10.1097/FPC.0b013e3282f75f88 CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant recipients
51. Clin Pharmacokinet Benkali 49 683 2010 10.2165/11535950-000000000-00000 Population pharmacokinetics and bayesian estimation of tacrolimus exposure in renal transplant recipients on a new once-daily formulation
52. Pharmacogenet Genomics Wehland 21 179 2011 10.1097/FPC.0b013e32833ea085 Differential impact of the CYP3A5*1 and CYP3A5*3 alleles on pre-dose concentrations of two tacrolimus formulations